DOvEEgene – Research Institute MUHC
HLD Confidence for Best Patient Care
About the Facility and Team
Developed by a team of McGill University Health Centre researchers, DOvEEgene is the new genomic uterine pap test. Whereas the conventional pap test screens for cervical cancer by finding abnormal cells under a microscope, the DOvEEgene test is developed to screen for both ovarian and endometrial cancers.
The cutting-edge DOvEEgene test is the only test capable of making the distinction between cancer and non-cancer cells in pre- and post-menpausal women. The full test process includes completing a questionnaire, collecting a saliva sample, a blood sample, a transvaginal ultrasound, a conventional pap-test and the DOvEEgene test.
The research team was working at the Royal Victoria Hospital in Montreal, and were using UV technology to disinfect their ultrasound probes. As they started looking into expanding operations to an additional location, they began the procurement process for another device for ultrasound probe high level disinfection (HLD). One of the DOvEEgene researchers had recently attended a conference and spoke with the Nanosonics team about trophon technology. After requesting a trophon2 demonstration, their team was impressed by the prompt response, expertise and professionalism from Nanosonics.
HLD Confidence for Best Patient Care
Upon seeing the trophon2 device in action, the DOvEEgene team quickly decided to implement it at point of care within their facility.
“Being able to show the device at point of care is very helpful and reassuring – our patients are aware of our processes, and ask a lot of questions because they want the safest solution. We feel comfortable discussing the HLD cycle with our patients, and confident that because the device is automated, there is no chance of human error.”Thao VuBSN, RN. Research Institute MUHC
“The trophon2 device is user-friendly, and the 7-minute cycle easily fits into our workflow between patients.”Thao VuBSN, RN. Research Institute MUHC
They also appreciated the trophon2 device’s sleek profile and portability, as on some occasions it needs to be transported to satellite clinics. Most importantly, they emphasized the need for patient and staff safety, and wanting to provide the highest standard of patient care.
"The trophon2 device checks all the boxes. We wouldn’t change anything about our HLD method, and would highly recommend trophon2 devices for other facilities.”Thao VuBSN, RN. Research Institute MUHC
